Wall Street rarely pays for the same drug twice. Once a big trial succeeds, the stock jumps and investors start asking what comes next.
That question gets louder when a company’s biggest product is heading toward a patent cliff. One hit can’t fill a revenue gap measured in tens of billions of…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.